Your Health, We Care
Another NameJyseleca、Fequintinib、LuciFilgo
IndicationsAdult patients with moderate to severe rheumatoid arthritis (RA) who have insufficient or intolerant response to various disease modifying antirheumatic drugs (DMARD).
Reg No.06 L 1112 /24
Inspection NO.1072-24
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
Filgotinib is a prescription drug targeting Janus kinase 1 (JAK1). It was first approved for marketing in the European Union and Japan in September 2020. It should be used strictly under medical supervision.
Janus kinase 1 (JAK1)
Route and frequency of administration for filgotinib: Oral, once daily.
The dosage of filgotinib should be adjusted according to the patient's actual condition. For specific adjustments, consult a physician and follow medical advice.
Recommended reading: Dosage and Administration of Filgotinib
Common side effects: Nausea, upper respiratory tract infections, etc.
Serious side effects: Serious infections (e.g., pneumonia), herpes zoster, etc.
Reference article: Side Effects of Filgotinib
Pregnancy: Filgotinib is contraindicated in pregnant patients.
Lactation: It is unknown whether this drug is excreted into human milk. Breastfeeding women should not use filgotinib.
1. Before treatment, a comprehensive evaluation by a specialist is mandatory, with strict screening for contraindications and close monitoring during therapy.
2. Filgotinib is primarily metabolized by the CES2 enzyme. Caution is required when co-administered with CES2 inhibitors (e.g., simvastatin).
3. During treatment and for a period before and after, live vaccines are prohibited.
from FDA，2023.07
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
